The drug might be manufactured on the group’s formulation manufacturing facility at SEZ, Ahmedabad, it added.
The drug is used with different HIV drugs to assist management HIV an infection. It helps to lower the quantity of HIV in a single’s physique in order that the immune system can work higher, Zydus Cadila stated.
The group now has 319 approvals and has thus far filed over 400 abbreviated new drug applications (ANDAs) because the graduation of its submitting course of, it added.
Shares of Cadila Healthcare, the listed entity of Zydus group had been buying and selling at Rs 639.95 per scrip on BSE, up 0.18 per cent from its earlier shut.